THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 96 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $109,605 | -16.7% | 12,219 | +4.3% | 0.00% | – |
Q4 2023 | $131,632 | +41.5% | 11,711 | +8.7% | 0.00% | – |
Q3 2023 | $93,014 | -23.6% | 10,778 | -8.4% | 0.00% | – |
Q2 2023 | $121,737 | -9.2% | 11,762 | -4.8% | 0.00% | – |
Q1 2023 | $134,073 | -14.5% | 12,357 | -11.6% | 0.00% | -100.0% |
Q4 2022 | $156,788 | +14.4% | 13,974 | +3.3% | 0.00% | 0.0% |
Q3 2022 | $137,000 | +15.1% | 13,528 | +2.8% | 0.00% | – |
Q2 2022 | $119,000 | -34.3% | 13,162 | -30.7% | 0.00% | – |
Q1 2022 | $181,000 | -30.4% | 18,981 | -19.2% | 0.00% | -100.0% |
Q4 2021 | $260,000 | +50.3% | 23,489 | +0.5% | 0.00% | – |
Q3 2021 | $173,000 | -53.4% | 23,383 | -8.5% | 0.00% | -100.0% |
Q2 2021 | $371,000 | -14.9% | 25,560 | +19.6% | 0.00% | 0.0% |
Q1 2021 | $436,000 | +21.4% | 21,367 | +5.7% | 0.00% | 0.0% |
Q4 2020 | $359,000 | +52.8% | 20,206 | +27.3% | 0.00% | 0.0% |
Q3 2020 | $235,000 | -31.5% | 15,872 | -2.8% | 0.00% | -50.0% |
Q2 2020 | $343,000 | +38.9% | 16,332 | +52.9% | 0.00% | 0.0% |
Q1 2020 | $247,000 | -48.0% | 10,683 | -41.7% | 0.00% | 0.0% |
Q4 2019 | $475,000 | +19.6% | 18,335 | -10.0% | 0.00% | 0.0% |
Q3 2019 | $397,000 | +15.7% | 20,365 | -2.9% | 0.00% | 0.0% |
Q2 2019 | $343,000 | -35.9% | 20,977 | -11.1% | 0.00% | -33.3% |
Q1 2019 | $535,000 | -10.4% | 23,588 | +1.0% | 0.00% | -25.0% |
Q4 2018 | $597,000 | -34.0% | 23,344 | -15.8% | 0.00% | -33.3% |
Q3 2018 | $905,000 | +39.0% | 27,713 | -3.4% | 0.01% | +50.0% |
Q2 2018 | $651,000 | -12.1% | 28,696 | -6.1% | 0.00% | -20.0% |
Q1 2018 | $741,000 | -24.8% | 30,556 | -13.6% | 0.01% | -28.6% |
Q4 2017 | $986,000 | -13.2% | 35,347 | +6.5% | 0.01% | -30.0% |
Q3 2017 | $1,136,000 | -8.2% | 33,190 | +6.8% | 0.01% | -16.7% |
Q2 2017 | $1,238,000 | +3.9% | 31,080 | -3.9% | 0.01% | 0.0% |
Q1 2017 | $1,191,000 | -8.3% | 32,342 | -20.7% | 0.01% | -14.3% |
Q4 2016 | $1,299,000 | +4.3% | 40,760 | +18.5% | 0.01% | -17.6% |
Q3 2016 | $1,246,000 | +38.0% | 34,394 | -13.5% | 0.02% | +41.7% |
Q2 2016 | $903,000 | +52.5% | 39,782 | +26.3% | 0.01% | +50.0% |
Q1 2016 | $592,000 | +4.4% | 31,502 | -8.9% | 0.01% | +14.3% |
Q4 2015 | $567,000 | +82.3% | 34,587 | +22.1% | 0.01% | +75.0% |
Q3 2015 | $311,000 | -21.1% | 28,321 | -6.3% | 0.00% | -20.0% |
Q2 2015 | $394,000 | -25.5% | 30,226 | -0.9% | 0.01% | -16.7% |
Q1 2015 | $529,000 | +34.3% | 30,512 | +15.6% | 0.01% | +20.0% |
Q4 2014 | $394,000 | +83.3% | 26,395 | +182.4% | 0.01% | +66.7% |
Q3 2014 | $215,000 | -45.3% | 9,346 | -24.1% | 0.00% | -40.0% |
Q2 2014 | $393,000 | – | 12,320 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |